{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:04:11Z","timestamp":1774451051051,"version":"3.50.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.4065\/81.10.1350","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T20:27:47Z","timestamp":1232742467000},"page":"1350-1358","source":"Crossref","is-referenced-by-count":21,"title":["Use of Antidementia Agents in Vascular Dementia: Beyond Alzheimer Disease"],"prefix":"10.4065","volume":"81","author":[{"given":"Martin R.","family":"Farlow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/81.10.1350_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00002512-199915050-00004","article-title":"Worldwide prevalence and incidence of dementia","volume":"15","author":"Fratiglioni","year":"1999","journal-title":"Drugs Aging"},{"key":"10.4065\/81.10.1350_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0022-510X(90)90236-G","article-title":"Senile dementia of Lewy body type: a clinically and neuropathologically distinct form of Lewy body dementia in the elderly","volume":"95","author":"Perry","year":"1990","journal-title":"J Neurol Sci"},{"key":"10.4065\/81.10.1350_bib3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0025-7125(02)00008-1","article-title":"Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention","volume":"86","author":"Rom\u00e1n","year":"2002","journal-title":"Med Clin North Am"},{"key":"10.4065\/81.10.1350_bib4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000026219","article-title":"Spectrum of disease in vascular cognitive impairment","volume":"18","author":"Rockwood","year":"1999","journal-title":"Neuroepidemiology"},{"key":"10.4065\/81.10.1350_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.1997.03540340047031","article-title":"Brain infarction and the clinical expression of Alzheimer disease: the Nun Study","volume":"277","author":"Snowdon","year":"1997","journal-title":"JAMA"},{"key":"10.4065\/81.10.1350_bib6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.STR.28.4.785","article-title":"Dementia three months after stroke: baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort","volume":"28","author":"Pohjasvaara","year":"1997","journal-title":"Stroke"},{"key":"10.4065\/81.10.1350_bib7","first-page":"117","article-title":"The new epidemic: frequency of dementia in the Rotterdam Study","volume":"28","author":"Breteler","year":"1998","journal-title":"Haemostasis"},{"key":"10.4065\/81.10.1350_bib8","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/01.STR.30.12.2523","article-title":"Incidence and occurrence of total (first-ever and recurrent) stroke","volume":"30","author":"Williams","year":"1999","journal-title":"Stroke"},{"key":"10.4065\/81.10.1350_bib9","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/jnnp.57.2.202","article-title":"Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities","volume":"57","author":"Tatemichi","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.4065\/81.10.1350_bib10","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1212\/WNL.57.11.1986","article-title":"Hypotension and cognitive impairment: selective association in patients with heart failure","volume":"57","author":"Zuccal\u00e0","year":"2001","journal-title":"Neurology"},{"key":"10.4065\/81.10.1350_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-510X(02)00252-6","article-title":"Vascular dementia may be the most common form of dementia in the elderly","volume":"203\u2013204","author":"Rom\u00e1n","year":"2002","journal-title":"J Neurol Sci"},{"key":"10.4065\/81.10.1350_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5694\/j.1326-5377.1999.tb126889.x","article-title":"Vascular dementia: diagnosis, management and possible prevention","volume":"170","author":"Sachdev","year":"1999","journal-title":"Med J Aust"},{"key":"10.4065\/81.10.1350_bib13","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1046\/j.1532-5415.5155.x","article-title":"Vascular dementia: distinguishing characteristics, treatment, and prevention","volume":"51","author":"Rom\u00e1n","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"10.4065\/81.10.1350_bib14","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.43.2.250","article-title":"Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop","volume":"43","author":"Rom\u00e1n","year":"1993","journal-title":"Neurology"},{"key":"10.4065\/81.10.1350_bib15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.4065\/81.10.1350_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer's disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.4065\/81.10.1350_bib17","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.410100203","article-title":"Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis","volume":"10","author":"Whitehouse","year":"1981","journal-title":"Ann Neurol"},{"key":"10.4065\/81.10.1350_bib18","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1136\/bmj.2.6150.1457","article-title":"Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia","volume":"2","author":"Perry","year":"1978","journal-title":"BMJ"},{"key":"10.4065\/81.10.1350_bib19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/1531-8249(200008)48:2<194::AID-ANA9>3.0.CO;2-X","article-title":"Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study","volume":"48","author":"Shinotoh","year":"2000","journal-title":"Ann Neurol"},{"key":"10.4065\/81.10.1350_bib20","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/BF01271206","article-title":"Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia","volume":"103","author":"Tohgi","year":"1996","journal-title":"J Neural Transm"},{"key":"10.4065\/81.10.1350_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/jscd.2003.5","article-title":"Strategic involvement of cholinergic pathways and executive dysfunction: does location of white matter signal hyperintensities matter?","volume":"12","author":"Swartz","year":"2003","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.4065\/81.10.1350_bib22","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.STR.0000091396.95360.E1","article-title":"Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial","volume":"34","author":"Black","year":"2003","journal-title":"Stroke"},{"key":"10.4065\/81.10.1350_bib23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/01.WNL.0000078943.50032.FC","article-title":"Donepezil in vascular dementia: a randomized, placebo-controlled study","volume":"61","author":"Wilkinson","year":"2003","journal-title":"Neurology"},{"key":"10.4065\/81.10.1350_bib24","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"10.4065\/81.10.1350_bib25","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0149-2918(03)80168-6","article-title":"An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia [published correction appears in Clin Ther. 2003;25:2336]","volume":"25","author":"Erkinjuntti","year":"2003","journal-title":"Clin Ther"},{"key":"10.4065\/81.10.1350_bib26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2165\/00023210-200317120-00004","article-title":"Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease","volume":"17","author":"Small","year":"2003","journal-title":"CNS Drugs"},{"key":"10.4065\/81.10.1350_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1468-1331.2003.00677.x","article-title":"Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease","volume":"10","author":"Kurz","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.4065\/81.10.1350_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1468-1331.2001.00224.x","article-title":"Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up [letter]","volume":"8","author":"Moretti","year":"2001","journal-title":"Eur J Neurol"},{"key":"10.4065\/81.10.1350_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0011-393X(02)80050-9","article-title":"An open-label pilot study comparing rivastigmine and low-dose aspirin for the treatment of symptoms specific to patients with subcortical vascular dementia","volume":"63","author":"Moretti","year":"2002","journal-title":"Curr Therapeut Res"},{"key":"10.4065\/81.10.1350_bib30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-510X(02)00280-0","article-title":"Rivastigmine in subcortical vascular dementia: an open 22-month study","volume":"203\u2013204","author":"Moretti","year":"2002","journal-title":"J Neurol Sci"},{"key":"10.4065\/81.10.1350_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/153331750301800508","article-title":"Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients","volume":"18","author":"Moretti","year":"2003","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.4065\/81.10.1350_bib32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1368-5031.2004.00127.x","article-title":"Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study","volume":"58","author":"Moretti","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.4065\/81.10.1350_bib33","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1161\/01.STR.0000020094.08790.49","article-title":"Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300)","volume":"33","author":"Orgogozo","year":"2002","journal-title":"Stroke"},{"key":"10.4065\/81.10.1350_bib34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00004850-200211000-00005","article-title":"A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)","volume":"17","author":"Wilcock","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"10.4065\/81.10.1350_bib35","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.4065\/81.10.1350_bib36","first-page":"1","article-title":"An overview of rating scales used in dementia research","volume":"2","author":"Schneider","year":"1996","journal-title":"Alzheimer Insights [serial online]"},{"key":"10.4065\/81.10.1350_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.4065\/81.10.1350_bib38","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1192\/bjp.140.6.566","article-title":"A new clinical scale for the staging of dementia","volume":"140","author":"Hughes","year":"1982","journal-title":"Br J Psychiatry"},{"key":"10.4065\/81.10.1350_bib39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/WNL.57.3.481","article-title":"A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [published correction appears in Neurology. 2001;57:1942]","volume":"57","author":"Mohs","year":"2001","journal-title":"Neurology"},{"key":"10.4065\/81.10.1350_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5014\/ajot.53.5.471","article-title":"Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia","volume":"53","author":"G\u00e9linas","year":"1999","journal-title":"Am J Occup Ther"},{"key":"10.4065\/81.10.1350_bib41","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1021\/jm00024a009","article-title":"Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds","volume":"38","author":"Sugimoto","year":"1995","journal-title":"J Med Chem"},{"key":"10.4065\/81.10.1350_bib42","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"10.4065\/81.10.1350_bib43","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer's disease\u2014results from a multinational trial","volume":"10","author":"Burns","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.4065\/81.10.1350_bib44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1212\/WNL.57.3.489","article-title":"A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD","volume":"57","author":"Winblad","year":"2001","journal-title":"Neurology"},{"key":"10.4065\/81.10.1350_bib45","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/WNL.57.4.613","article-title":"A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published correction appears in Neurology. 2001;57:2153]","volume":"57","author":"Feldman","year":"2001","journal-title":"Neurology"},{"key":"10.4065\/81.10.1350_bib46","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","article-title":"The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease","volume":"63","author":"Holmes","year":"2004","journal-title":"Neurology"},{"issue":"suppl 2","key":"10.4065\/81.10.1350_bib47","first-page":"256","article-title":"Donepezil provides significant benefits on cognition, global function, and activities of daily living in patients with vascular dementia [abstract]?","volume":"15","author":"Farcnik","year":"2003","journal-title":"Int Psychogeriatr"},{"key":"10.4065\/81.10.1350_bib48","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"10.4065\/81.10.1350_bib49","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.4065\/81.10.1350_bib50","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial [published correction appears in BMJ. 2001;322:405]","volume":"321","author":"Wilcock","year":"2000","journal-title":"BMJ"},{"key":"10.4065\/81.10.1350_bib51","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial","volume":"71","author":"Rockwood","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.4065\/81.10.1350_bib52","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial [published correction appears in BMJ. 2001;322:1456]","volume":"318","author":"Rosler","year":"1999","journal-title":"BMJ"},{"key":"10.4065\/81.10.1350_bib53","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archneur.60.6.843","article-title":"Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial","volume":"60","author":"Farlow","year":"2003","journal-title":"Arch Neurol"},{"issue":"suppl","key":"10.4065\/81.10.1350_bib54","first-page":"9","article-title":"Behavioral symptoms in Alzheimer's disease: phenomenology and treatment","volume":"48","author":"Reisberg","year":"1987","journal-title":"J Clin Psychiatry"},{"key":"10.4065\/81.10.1350_bib55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validation of a geriatric depression screening scale: a preliminary report","volume":"17","author":"Yesavage","year":"1982","journal-title":"J Psychiatr Res"},{"key":"10.4065\/81.10.1350_bib56","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00002093-198802040-00003","article-title":"Aggressive behavior in persons with dementia who live in the community","volume":"2","author":"Ryden","year":"1988","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.4065\/81.10.1350_bib57","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer's disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med"},{"key":"10.4065\/81.10.1350_bib58","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0167-4943(82)90031-0","article-title":"A new rating scale for dementia syndromes","volume":"1","author":"Gottfries","year":"1982","journal-title":"Arch Gerontol Geriatr"},{"key":"10.4065\/81.10.1350_bib59","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1532-5415.1991.tb02897.x","article-title":"A new behavioral assessment scale for geriatric out- and in-patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients)","volume":"39","author":"Spiegel","year":"1991","journal-title":"J Am Geriatr Soc"},{"key":"10.4065\/81.10.1350_bib60","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2165\/00002512-200320150-00005","article-title":"Donepezil: in vascular dementia","volume":"20","author":"Goldsmith","year":"2003","journal-title":"Drugs Aging"},{"key":"10.4065\/81.10.1350_bib61","first-page":"181","article-title":"Donepezil minimally effective for patients with vascular dementia","volume":"53","author":"Johnson","year":"2004","journal-title":"J Fam Pract"},{"key":"10.4065\/81.10.1350_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004395.pub2","article-title":"Donepezil for vascular cognitive impairment?","volume":"1","author":"Malouf","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.4065\/81.10.1350_bib63","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1358\/dot.2004.40.8.850471","article-title":"Memantine hydrochloride: pharmacological and clinical profile","volume":"40","author":"Mobius","year":"2004","journal-title":"Drugs Today (Barc)"},{"key":"10.4065\/81.10.1350_bib64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/08039480510022936","article-title":"Drug therapy of dementia in elderly patients: a review","volume":"59","author":"Olsen","year":"2005","journal-title":"Nord J Psychiatry"},{"issue":"suppl 1","key":"10.4065\/81.10.1350_bib65","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1017\/S1041610203009190","article-title":"Patient populations in clinical studies of donepezil in vascular dementia","volume":"15","author":"Pratt","year":"2003","journal-title":"Int Psychogeriatr"},{"key":"10.4065\/81.10.1350_bib66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-510X(02)00266-6","article-title":"Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia","volume":"203\u2013204","author":"Pratt","year":"2002","journal-title":"J Neurol Sci"},{"key":"10.4065\/81.10.1350_bib67","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000088494","article-title":"Donepezil in vascular dementia: combined analysis of two large-scale clinical trials","volume":"20","author":"Roman","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.4065\/81.10.1350_bib68","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.amjopharm.2004.12.006","article-title":"Efficacy and tolerability of memantine in the treatment of dementia","volume":"2","author":"Rossom","year":"2004","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.4065\/81.10.1350_bib69","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.nrl.0000087723.53475.48","article-title":"Update on Alzheimer drugs (donepezil)","volume":"9","author":"Doody","year":"2003","journal-title":"Neurologist"},{"key":"10.4065\/81.10.1350_bib70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000074140","article-title":"Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine","volume":"17","author":"Bullock","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.4065\/81.10.1350_bib71","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1586\/14737175.4.2.153","article-title":"Galantamine: use in Alzheimer's disease and related disorders","volume":"4","author":"Bullock","year":"2004","journal-title":"Expert Rev Neurother"},{"key":"10.4065\/81.10.1350_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004746.pub2","article-title":"Galantamine for vascular cognitive impairment?","volume":"1","author":"Craig","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.4065\/81.10.1350_bib73","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11910-002-0036-z","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial","volume":"2","author":"Kertesz","year":"2002","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.4065\/81.10.1350_bib74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1034\/j.1600-0404.106.s178.5.x","article-title":"Non-cognitive benefits of galantamine (Reminyl) treatment in vascular dementia","volume":"178","author":"Kurz","year":"2002","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.4065\/81.10.1350_bib75","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11910-002-0062-x","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial [editorial]","volume":"2","author":"Marder","year":"2002","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.4065\/81.10.1350_bib76","article-title":"Rivastigmine for vascular cognitive impairment","volume":"2","author":"Craig","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.4065\/81.10.1350_bib77","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1517\/14656566.5.6.1399","article-title":"Rivastigmine in vascular dementia","volume":"5","author":"Moretti","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.4065\/81.10.1350_bib78","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1586\/14737175.5.3.309","article-title":"Rivastigmine for subcortical vascular dementia","volume":"5","author":"Roman","year":"2005","journal-title":"Expert Rev Neurother"},{"issue":"suppl 1","key":"10.4065\/81.10.1350_bib79","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1017\/S1041610203009207","article-title":"Rivastigmine in vascular dementia","volume":"15","author":"Vincent","year":"2003","journal-title":"Int Psychogeriatr"},{"key":"10.4065\/81.10.1350_bib80","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s00213-005-0083-7","article-title":"Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects","volume":"181","author":"Wezenberg","year":"2005","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611611592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611611592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T10:07:11Z","timestamp":1558087631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611611592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":80,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0025619611611592"],"URL":"https:\/\/doi.org\/10.4065\/81.10.1350","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}